Abbott's Q3 MDx Sales Rise 15 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Abbott today reported that its third quarter revenues increased 2 percent year over year, with a decline in pharmaceuticals sales offset by gains in its diagnostics business.

Overall, the firm reported sales of $5.37 billion, up from $5.27 million for the third quarter of 2012. Abbott's Nutrition and Medical Devices businesses both reported 2 percent revenue gains year over year, while Pharmaceuticals fell 3 percent. Its Diagnostics business, however, reported sales growth of 8 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.